Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

October 31, 1999

Primary Completion Date

October 31, 2002

Study Completion Date

March 31, 2007

Conditions
Leukemia
Interventions
BIOLOGICAL

filgrastim

DRUG

asparaginase

DRUG

cytarabine

DRUG

daunorubicin hydrochloride

DRUG

melphalan

DRUG

thioguanine

PROCEDURE

peripheral blood stem cell transplantation

Trial Locations (20)

10029

Mount Sinai School of Medicine, New York

21231

Johns Hopkins Oncology Center, Baltimore

30322

Emory University Hospital - Atlanta, Atlanta

32207

Nemours Children's Clinic, Jacksonville

35294

University of Alabama Comprehensive Cancer Center, Birmingham

48201

Children's Hospital of Michigan, Detroit

53226

Midwest Children's Cancer Center, Milwaukee

60614

Children's Memorial Hospital, Chicago, Chicago

63104

Cardinal Glennon Children's Hospital, St Louis

72205

University of Arkansas for Medical Sciences, Little Rock

76104

Cook Children's Medical Center - Fort Worth, Fort Worth

85724

Arizona Cancer Center, Tucson

94304

Lucile Packard Children's Hospital at Stanford, Palo Alto

92123-4282

Children's Hospital and Health Center, San Diego

04074

Maine Children's Cancer Program, Scarborough

02114

Massachusetts General Hospital Cancer Center, Boston

07601

Hackensack University Medical Center, Hackensack

Tomorrows Children's Institute, Hackensack

75235-9154

Simmons Cancer Center - Dallas, Dallas

H3H 1P3

Montreal Children's Hospital, Montreal

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK

NCT00004056 - Combination Chemotherapy Followed by Melphalan and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter